Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Clin Genitourin Cancer. 2017 Oct 24;16(2):e469–e476. doi: 10.1016/j.clgc.2017.10.010

Figure 3. Ra223 treatment does not alter the frequency of CD8+ T cells producing IFN-γ, TNF-α and IL-13 in patients with mCPRC.

Figure 3

PBMCs were purified from the peripheral blood of patients with mCPRC and stimulated for 4 hours with or without PMA/ionomycin in the presence of Brefeldin A. Stimulated cells were stained with antibodies to CD3, CD8, CD45RA and CCR7, fixed and permeabilized followed by IFN-γ, TNF-α or IL-13 staining. Flow cytometric analysis was done to determine the frequency of cells producing IFN-γ, TNF-α or IL-13 in CD8+ T cells. (A) Representative contour plots showing IFN-γ, TNF-α or IL-13 producing CD8+ T cells stimulated for 4 hours with or without PMA/ionomycin. Numbers in the plots indicate the frequency of cytokine producing cells. (B) Frequency of IFN-γ, TNF-α or IL-13 producing cells in CD8+ T cells of patients with mCPRC before and after Ra223 treatment as measured by flow cytometry. Bars and error bars indicate mean ± SEM. P-value was obtained by the paired Student t-test.